– USA, MA – Finch Therapeutics Group, Inc. (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today announced the appointment of Susan Graf to its Board of Directors as Chair of the Audit Committee.
Susan Graf is an accomplished biopharma executive with more than 25 years of experience spanning corporate strategy, finance, business development, M&A, and the development and commercialization of biopharmaceuticals.
“On behalf of the Finch team, I am delighted to welcome Susan to our board,” said CEO, Dr. Mark Smith. “Susan’s extensive experience and demonstrated ability to guide the strategic growth of organizations and enable the development of new therapeutics will be invaluable as we continue to rapidly advance our pipeline, platform, and this new modality.”
About Susan Graf
Ms. Graf currently serves as CEO of Akamara Therapeutics. Before Akamara, she was Chief Business Officer and Principal Financial Officer at Epizyme, Inc., leading finance, investor relations, corporate and business development, and alliance management as well as implementing Epizyme’s corporate strategy. Before Epizyme, Ms. Graf held the position of VP, Corporate Development and Strategy for NPS Pharma before it was acquired by Shire in 2015. She was closely involved in the company’s sale to Shire for $5.2B, in addition to serving on the executive team that transformed NPS Pharma into a global, commercial-stage, rare-disease biopharmaceutical company. During her tenure, NPS Pharma brought two rare disease products – Gattex and Natpara– to market. Before NPS Pharma, Ms. Graf spent nearly 18 years at Roche in several leadership and executive positions in business development, commercial assessment, due diligence, mergers & acquisitions, marketing, market research, sales, and manufacturing.
“With Finch’s recent IPO, strong Phase 2 data from their lead candidate, and innovative programs in chronic hepatitis B and autism entering the clinic soon, I am thrilled to join Finch at this exciting time,” said Susan Graf. “I look forward to working with Finch’s board and leadership team to execute on Finch’s strategy and its mission to serve patients.”
Ms. Graf has an MBA from the Stern School of Business at New York University and a Bachelor of Pharmacy degree from Purdue University.
About Finch Therapeutics
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn’s disease, respectively.
For more information: https://www.finchtherapeutics.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.